Skip to main content

Table 1 Correlation of BCL2 expression with clinic-pathologic characteristics in AML among TCGA cohort

From: BCL2 overexpression: clinical implication and biological insights in acute myeloid leukemia

Patient’s parameters

BCL2 expression

Low (n = 87)

High (n = 86)

P

Sex, male/female

49/38

43/43

0.448

Median age, years (range)

61 (22–82)

56 (18–88)

0.106

Median WBC, ×109/L (range)

17.9 (0.6–223.8)

15.25 (0.4–297.4)

0.041

Median PB blasts, % (range)

24 (0–94)

46 (0–98)

0.033

Median BM blasts, % (range)

73 (30–98)

72 (30–100)

0.893

FAB classifications

  

0.000

 M0

4

12

0.038

 M1

15

29

0.015

 M2

21

17

NS

 M3

5

11

NS

 M4

22

12

NS

 M5

16

2

0.001

 M6

1

1

NS

 M7

1

2

NS

 No data

2

0

NS

Cytogenetics

  

0.239

 Normal

44

32

NS

 t(15;17)

5

10

NS

 t(8;21)

6

1

NS

 inv.(16)

3

7

NS

  + 8

3

5

NS

 del(5)

0

1

NS

 -7/del(7)

4

4

NS

 11q23

2

1

NS

 Others

10

9

NS

 Complex

9

15

NS

 No data

1

1

NS

Gene mutation

 FLT3 (+/−)

23/64

26/60

0.616

 NPM1 (+/−)

28/59

20/66

0.235

 DNMT3A (+/−)

23/64

19/67

0.595

 IDH2 (+/−)

9/78

8/78

1.000

 IDH1 (+/−)

5/82

11/75

0.124

 TET2 (+/−)

9/78

6/80

0.590

 RUNX1 (+/−)

5/82

10/76

0.188

 TP53 (+/−)

6/81

8/78

0.590

 NRAS (+/−)

5/82

7/79

0.566

 CEBPA (+/−)

7/80

6/80

1.000

 WT1 (+/−)

2/85

8/78

0.057

 PTPN11 (+/−)

3/84

5/81

0.496

 KIT (+/−)

5/82

2/84

0.443

 U2AF1 (+/−)

4/83

3/83

1.000

 KRAS (+/−)

4/83

3/83

1.000

 SMC1A (+/−)

5/82

2/84

0.443

 SMC3 (+/−)

4/83

3/83

1.000

 PHF6 (+/−)

1/86

4/82

0.211

 STAG2 (+/−)

2/85

3/83

0.682

 RAD21 (+/−)

4/83

0/86

0.121

  1. AML acute myeloid leukemia, WBC white blood cells, PB peripheral blood, BM bone marrow, FAB French-American-British classification, NS no significant